HRA Pharma

Company snapshot

HRA Pharma is a fast growing, innovative consumer healthcare company, empowering people throughout the world to improve their lives by developing accessible, value added, self-care solutions. Historically centered on women’s health, the company has become the European leader in emergency contraception and in compromised skin. With ambitious projects in the pipeline, including innovative Rx-to-OTC

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for HRA Pharma. Not investment advice.

• Peer + 0 momentum

  Aldeyra Therapeutics

  TA overlap score 25.2

Recent activity

Latest pipeline, patent, and corporate events for HRA Pharma.

1. Jun 8, 2026 Clinical update

   SB-421a-006 — Phase 2

2. Jun 8, 2026 Clinical update

   SB-421a-006 — Phase 2

3. Jun 8, 2026 Clinical update

   ARG-01-2024 — Phase 3

4. Jun 8, 2026 Clinical update

   Coagulation Factor VIIa (Recombinant) — Phase 3

5. Jun 8, 2026 Clinical update

   D-CURE 25000 UI gélules., Placebo of vitamin D — Approved

View all clinical trial activity →

• What is HRA Pharma?

  Laboratoire HRA Pharma is a pharma organization headquartered in CHATILLON, FR. Primary therapeutic focus areas include Retinitis Pigmentosa, Dyslipidaemia, Hemophilia, Allergic Conjunctivitis, Leber congenital amaurosis (LCA). NovaPharmaNews links 11 clinical program(s), 0 drug

• Is HRA Pharma publicly traded?

  HRA Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does HRA Pharma develop or market?

  We link 17 drug profile(s) where HRA Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/laboratoire-hra-pharma#company-drugs.

• What are the latest developments for HRA Pharma?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does HRA Pharma focus on?

  HRA Pharma focuses on Retinitis Pigmentosa, Dyslipidaemia, Hemophilia based on our analysis of their pipeline programs and drug development activities.